Different antimuscarinics when combined with atomoxetine have differential effects on obstructive sleep apnea severity
Atqiya Aishah, Richard Lim, Scott A. Sands, Luigi Taranto‐Montemurro, Andrew Wellman, Jayne C. Carberry, Danny J. Eckert
Abstract
In contrast to recent findings of major reductions in OSA severity when atomoxetine is combined with a nonspecific antimuscarinic, oxybutynin (broad M-subtype receptor selectivity), addition of solifenacin succinate (M2 and M3 muscarinic receptor selectivity) or biperiden (M1 muscarinic receptor selectivity) with atomoxetine had modest effects on upper airway function during sleep, which provide mechanistic insight into the role of noradrenergic and antimuscarinic agents on sleep and breathing and are important for pharmacotherapy development for OSA.
Topics & Concepts
Obstructive sleep apneaAtomoxetineOxybutyninMedicineApneaDifferential effectsSleep apneaAnesthesiaInternal medicinePsychiatryPathologyAttention deficit hyperactivity disorderOveractive bladderAlternative medicineMethylphenidateObstructive Sleep Apnea ResearchNeuroscience of respiration and sleepSleep and Wakefulness Research